Successful Conclusion of the United States–United Kingdom Arrangement on Pharmaceutical Pricing

WASHINGTON - Today, United States Trade Representative Jamieson Greer, Health and Human Services Secretary Robert F. Kennedy, Jr, and Commerce Secretary Howard Lutnick issued the following statements announcing an arrangement on pharmaceutical pricing between the United States and the United Kingdom.

"President Trump is ensuring our trading partners pay their fair share for innovative pharmaceutical products, so that American patients are not shouldering the burden of funding research and development for the next generation of life-saving medicines," said Ambassador Jamieson Greer. "Today's Arrangement addresses long-standing imbalances in the U.S.-UK pharmaceutical trade while driving investment and development in both our countries. I thank the United Kingdom for its commitment to support positive patient outcomes by improving access to medicines, strengthening supply chains, and promoting mutually beneficial trade between our countries."

"President Trump's agreement with the United Kingdom is another big step toward ending a system that forces Americans to pay more so others can pay less," said Health and Human Services Secretary Robert F. Kennedy, Jr. "American patients deserve the same affordable access to the medicines they need as patients in the UK."

"Today's agreement on pharmaceutical pricing is a major win for Americans and our innovation economy. It strengthens supply chains, expands Most Favored affordable access to life-saving drugs, and reinforces America as the world's premier hub for life sciences investment," said Secretary Howard Lutnick. "This agreement not only deepens our economic partnership with the United Kingdom and their leading pharmaceutical companies, but also helps ensure that tomorrow's breakthroughs are accessible, affordable, and, manufactured on American soil."

To read the text of the Arrangement Between the Government of the United States of America and the Government of the United Kingdom of Great Britain and Northern Ireland on Pharmaceutical Pricing, click here.

###